Paediatric Respiratory Reviews
Volume 10, Issue 3 , Pages 124-133 , September 2009

Genetics terminology for respiratory physicians

  • Felicity A. Collins

      Affiliations

    • Corresponding Author InformationDiscipline of Paediatrics & Child Health, and Discipline of Genetic Medicine, University of Sydney, Sydney, New South Wales, Australia. Tel.: +61 2 9845 3273; Fax: +61 2 9845 3204.

References 

  1. International Human Genome Sequencing Consortium . Finishing the euchromatic sequence of the human genome. Nature. 2004;431:931–945
  2. NHS Genetics White Paper. “Our Inheritance – Our Future”: Realising the potential of Genetics in the NHS. UK: Department of Health 2003.
  3. Family Health History Initiative. National Human Genome Research Institute and Office of Surgeon General, Department of Health and Human Services. 2004.
  4. Collins FS, Green ED, Guttmacher AE, Guyer MS. A vision for the future of genomics research. Nature. 2003 April 24;422:835–847
  5. Watson JD, Crick F. Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid. Nature. 1953;171:737–738
  6. Birney E, Stamatoyannopoulos JA, DuttaA , et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE project. Nature. 2007;447:799–816
  7. Bobadilla JC, Macek M, Fine JP, et al. Cystic Fibrosis: A worldwide analysis of CFTR mutations – correlation with incidence data and application to screening. Human Mutation. 2002;19:575–606
  8. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterisation of complementary DNA. Science. 1989;245:1066–1073
  9. McIntosh I, Cutting GR. Cystic fibrosis transmembrane conductance regulator and the etiology and pathogenesis of cystic fibrosis. FASEB J. 1992;6:2775–2782
  10. CF Mutation database: http://www.genet.sickkids.on.ca/cftr/.
  11. Ogino S, Gulley ML, den Dunnen JT, et al. Standard Mutation nomenclature in molecular diagnostics. J Mol Diagn. 2007;9:1–6
  12. Kerem E, Kerem B. Genotype-phenotype correlations in cystic fibrosis. Pediatr Pulm. 1996;20:387–395
  13. Rowntree RK, Harris A. The phenotypic consequences of CFTR mutations. Ann Hum Genet. 2003;67:471–485
  14. Rowe SM, Miller S, Sorscher EJ. Mechanisms of disease. Cystic Fibrosis. NEJM. 2005;19:1992–2001
  15. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 1993;73:1251–1254
  16. Wilschanski M, Zielenski J, Markiewicz D, Tsui LC, et al. Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations. J Pediat. 1995;127:705–710
  17. Noone PG, Pue CA, Zhou Z, et al. Lung disease associated with the IVS8 5T allele of the CFTR gene. Am J Respir Crit Care Med. 2000;162:1919–1924
  18. Collaco JM, Gutting GR. Update on genetic modifiers in cystic fibrosis. Curr Opin Pulm Med. 2008 Nov;14:559–566
  19. Griffin DK, Finch KA. The genetic and cytogenetic basis of male infertility. Human Fertility. 2005;8:19–26
  20. Proesmans M, Vermeulen F, De Boeck K. What's new in cystic fibrosis? From treating symptoms to correction of the basic defect. Eur J Pediatr. 2008 Aug;167:839–849
  21. Dork T, Dworniczak B, Aulehla-Scholz C, et al. Distinct spectrum of CFTR gene mutations in congenital absence of the vas deferens. Hum Genet. 1997 Sep;100:365–377
  22. Claustres M, Guittard C, Bozon D, et al. Spectrum of CFTR mutations in cystric fibrosis and in congenital absence of the vas deferens in France. Hum Mutat. 2000;16:143–156
  23. Wang Z, Milunsky J, Yamin M, et al. Analysis by mass spectrometry of 100 cystic fibrosis gene mutations in 92 patients with congenital absence of the vas deferens. Hum Reprod. 2002 Aug;17:2066–2072
  24. Moskowitz SM, Chmiel JF, Sternen DL, et al. Gene reviews – CFTR related disorders 2008. University of Washington, Seattle at http://www.genetests.org.
  25. Moffat MF. Genes in asthma: new genes and new ways. Curr Opin Allergy Clin Immunol. 2008;8:411–417
  26. Vercelli D. Discovering susceptibility genes for asthma and allergy. Nat Rev Immunol. 2008;8:169–182
  27. Lander ES, Linton LM, Birren B, et al. International Human Genome Sequencing consortium Initial sequencing and analysis of the human genome. Nature. 2001;409:860–921
  28. Schork NJ, Fallin D, Lanchbury S. Single nucleotide polymorphisms and the future of genetic epidemiology. Clin Genet. 2000;58:250–264
  29. Jeffreys AJ, Wilson V, Thein SL. Hypervariable minisatellite regions in human DNA. Nature. 1985;314:67–73
  30. Frazer KA, Ballinger DG, Cox DR, et al. International HapMap consortium. A second generation human haplotype map of over 3.2 million SNPs. Nature. 2007;449:851–861
  31. Beckmann JS, Estivill X, Antonarakis SE. Copy number variants and genetics traits: closer to resolutions of phenotypic to genotypic variability. Nature. 2001;8:639–646
  32. Weber JL, May PE. Abundant class of DNA polymorphisms which can be typed using polymerase chain reaction. Am J Hum Genet. 1989;44:388–396
  33. Botstein D, White RL, Skolnick M, Davis RW. Construction of a genetic linkage map using restriction fragment length polymorphisms. Am J Hum Genet. 1980;32:314–331
  34. Orr N, Chanock S. Common Genetic Variation and Human Disease. Adv in Genetics. 2008;62:1–32
  35. Krawezak M, Reiss J, Cooper DN. The mutational spectrum of single base-pair nucleotides in mRNA splice junctions of human genes: cause and consequences. Hum Genet. 1992;90:41–54
  36. Sachidanandam R, Weissman D, Schmidt SC, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001;409:928–933
  37. FeukL , Lakshmi B, Troge J, et al. Structural variation in the human genome. Nat Rev. Genet. 2006;7:85–97
  38. Sebat J, Lakshmi B, Troge J, et al. Large-scale copy number polymorphism in the human genome. Science. 2004;305:525–528
  39. Sebat J, Lakshmi B, Malhotra D, et al. Strong association of de novo copy number mutations with autism. Science. 2007;316:848–853
  40. Stranger BE, Forrest MS, Dunning M, et al. Relative impact of nucleotides and copy number variation on gene expression phenotypes. Science. 2007;315:848–853
  41. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245:1073–1080
  42. Conrad DF, Kajobsson M, Coop G, et al. A worldwide survey of haplotype variation and linkage disequilibrium in the human genome. Nat Genet. 2006;38:1251–1260
  43. International HapMap Project. http://www.hapmap.org.
  44. Hopes E, McDougall C, Christie G, et al. Association of glutamine 27 polymorphism of B2 adrenoceptor with reported childhood asthmas: population based study. BMJ. 1998;316:664
  45. Howard TD, Koppelman GH, Xu J, et al. Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with asthma. Am J Hum Genet. 2002;70:230–236
  46. Moffatt MF, Schou C, Faux JA, et al. Association between quantitative traits underlying asthma and the HLA-DRB1 locus in a family-based population sample. Eur J Hum Genet. 2000;9(5):341–346
  47. Krynetski EY, Tai HL. Yates CR> Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics. 1996;6(4):279–290
  48. Corvol H, Burchard EG. Pharmacogenetic response to albuterol among asthmatics. Pharmacogenomics. 2008;9:505–510
  49. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype- stratified, randomised, placebo-controlled cross-over trial. Lancet. 2004;364:1505–1512
  50. Tsai HJ, Shaikh N, Kho Jy , et al. Beta 2 adrenergic receptor polymorphisms: pharmacogenetic response to bronchodilator among African American asthmatics. Hum Genet. 2006;119(5):547–557
  51. Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatics: results of two phase 2a studies. Lancet. 2007;370:1422–1431
  52. Tan Z, Randall G, Fan J, et al. Allele-specific targetting of microRNAs to HLA-G and risk of asthma. AJHG. 2007;81:829–834
  53. UK cystic fibrosis gene therapy consortium at http://www.cfgenetherapy.org.uk/.
  54. Noone PG, Hohneker KW, Zhou Z, et al. Safety and biological efficacy of a lipid-CFTR complex for gene transfer in the nasal epithelium of adult patients with cystic fibrosis. Mol Ther. 2000;1:105–114
  55. Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. NEJM. 2003;349:1433–1441
  56. PTC Therapeutics company website www.ptcbio.com.
  57. US government clinical trials at www.clinicaltrials.gov/.
  58. Lukacs GL, Durie PR. Pharmacologic Approaches to correcting the basic defect in cystic fibrosis. NEJM. 2003;349:1401–1404
  59. Berger AL, Randak CO, Ostedgaarg LS, et al. Curcumin stimulates cystic fibrosis transmembrane conductance regulator Cl- channel activity. J Biolog Chem. 2005;280:5221–5226
  60. Evans WE, McLeod HL. Pharmacogenomics--drug disposition, drug targets, and side effects. New Eng. J. Med. 2003;348:538–549

PII: S1526-0542(09)00037-2

doi: 10.1016/j.prrv.2009.04.003

Paediatric Respiratory Reviews
Volume 10, Issue 3 , Pages 124-133 , September 2009

Article Tools

* Image Usage & Resolution